Waters Introduces Revolutionary Reversed-Phase Bioseparation Columns Enhancing GLP-1 and LNP Analysis Efficiency

Waters Corporation Unveils Innovative Reversed-Phase Bioseparation Columns

Waters Corporation, a recognized leader in analytical technologies, has recently unveiled an unprecedented series of reversed-phase bioseparation columns aimed at revolutionizing the field of biopharmaceutical analysis. Announced during the prestigious 55th International Symposium on High Performance Liquid Phase Separations and Related Techniques, these new products promise to dramatically enhance the efficiency of the characterization of GLP-1 peptides and the analysis of lipid nanoparticles (LNPs).

The newly introduced BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and C18+ columns are specifically designed to address complex challenges in biopharmaceutical testing. One of the standout features of these columns is their ability to deliver up to three times faster analysis for GLP-1 characterization and twice the speed for LNP component analysis. This speed increase is crucial in expediting drug development timelines while minimizing production bottlenecks, a persistent issue in today’s biopharmaceutical landscape.

Challenges in Biopharmaceutical Analysis

Biopharmaceuticals, especially GLP-1 receptor agonists and cutting-edge mRNA therapies, often face significant hurdles during analysis. Traditional reversed-phase columns struggle to provide clear separation of closely related impurities, which can lead to delayed time-to-market timelines and reduced confidence from regulatory bodies, ultimately impacting patient safety.

“The BioResolve Peptide and GTxResolve Lipid Columns represent a significant leap forward in chromatography,” remarked Erin Chambers, Vice President and General Manager at Waters Analytical Sciences. “By employing advanced chemical and physical particle technologies, we have created columns that users find both efficient and exceptionally reliable for their analysis of GLP-1 and lipid nanoparticles, specifically QC batch-tested for optimal performance.”

Enhanced Performance and Resolving Power

Notably, these columns not only increase analysis speed but also boast enhanced resolving power and sensitivity. By optimizing the design of the column materials, the BioResolve and GTxResolve columns can effectively identify and track low-level impurities, which is imperative for ensuring regulatory compliance and enhancing the safety of therapeutic products.

Customers have praised the BioResolve Peptide RP Columns for their performance in identifying critical impurities among complex GLP-1 peptides. For instance, Ashish Kanhed, Group Leader at Alembic Pharmaceuticals, remarked about the exceptional resolution these columns provide between peptide therapeutics and related impurities, enabling more efficient regulatory compliance. “We can now confidently assess molecular purity in shorter run times, without sacrificing accuracy,” he noted.

Addressing Specific LNP Challenges

The GTxResolve Lipid columns cater specifically to the intricate demands of lipid analysis. With a specially charged surface, these columns assist in sharpening peaks for ionizable lipids, thus enhancing peak shape and resolving challenging co-elutions. Feedback from analytical development scientists indicates the columns have successfully achieved separations that were previously unattainable in lipid workflows.

Adam Kowalczyk, Research Scientist at Acuitas Therapeutics, shared positive experiences with the GTxResolve columns, stating that they demonstrated robust performance for lipid quantitation with minimized run times and superior peak shape. This level of reliability is critical for the successful analysis of diverse lipid species, especially as therapies evolve.

Availability and Future Prospects

Waters’ innovative BioResolve Peptide and GTxResolve Lipid Column line is expected to be available globally starting June 9, 2026, beginning with the 1.6 µm Phenyl-Hexyl+ phase. The strategic development of these columns is expected to support not only the current demands of the biopharmaceutical industry but also pave the way for future advances in drug development through superior separation techniques.

This development highlights Waters Corporation’s commitment to leveraging deep scientific expertise to accelerate the launch of high-quality medicines. The new columns bolster the company’s portfolio while reinforcing their dedication to improving lives through scientific innovations.

For more information about these products and their applications, visit waters.com/BioResolve and waters.com/GTx.